Biotech Fund Doubles Down: Scholar Rock Bet Drives 26% Rally
A major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...
Identify situations where TRI provides a fuller view of performance than a price index, especially when dividends and compounding matter to total returns.
26,863 articlesA major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...
Costco has built a durable earnings engine on membership loyalty and disciplined spending. This guide breaks down wha...
Nebius stock fell today after the company announced debt issuance to fund its infrastructure push and key AI partners...
Nokia climbs on 5G demand and North American telecom spend, while broader markets drift. A practical look at what thi...
Two leading banks issued contrasting views on AMD in a single day, underscoring a broader divide in how investors pri...
A prominent Hyperliquid holder dumped about $9 million worth of HYPE as the token surged to new highs, underscoring a...
Strategy disclosed a record unrealized loss on its Bitcoin holdings, topping $10 billion as bitcoin trades near $61,0...
When energy costs rise, investors often look for EV players that could benefit. This article unpack Rivian's path to ...
Is DraftKings stock analysis signaling a sell or a hold? This deep dive breaks down how regulation, competition, and ...
Tesla stock has rebounded in recent sessions, creating a balanced risk-reward outlook as markets await the Q2 deliver...
A MeiraGTx insider recently sold shares as the biotech nears two pivotal drug filings. This article breaks down what ...
Two private-credit funds unveiled exit options for locked-up investors, offering steep discounts and renewed liquidit...